Adam Friedman, MD, returned from the 2025 AAD Annual Meeting with renewed optimism about emerging treatment options for chronic spontaneous urticaria (CSU), particularly the promising data on remibrutinib and the anticipated expanded indication for dupilumab. He emphasized the importance of offering patients hope by sharing that more targeted therapies are on the horizon.
Additionally, his research into the role of diet in CSU management led him to explore the potential benefits of Mediterranean and low-histamine diets, as well as vitamin D supplementation, as adjunctive therapies. He also reflected on the financial and emotional burdens of CSU, stressing the need for greater awareness of these challenges to improve patient care and communication.
